Pain Programs: Overview

Arcion is developing a pipeline of product candidates to treat neuropathic pain, a complex and debilitating chronic pain state. The company's focus on innovative topical treatments leverages expertise in understanding the biology underlying the neuropathic pain condition in order to rapidly advance new therapeutics that provide pain relief with convenient application and reduced systemic side effects. Arcion's lead clinical program, ARC-4558, is a 0.1% gel formulation of clonidine hycrochloride for topical administration. ARC-4558 is currently in a Phase 2b clinical trial for the treatment of painful diabetic neuropathy (PDN). Arcion intends to develop additional product candidates for multiple chronic and neuropathic pain conditions, including post-herpetic neuralgia (PHN).

"Arcion is developing a pipeline of topical product candidates to treat neuropathic pain."